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ABSTRACT 
The objective of the present study was to formulate and evaluate Effervescent Floating Tablet of Fluoxetine for the treatment of antidepressant 
agent. Tablets were prepared by direct compression using directly compressible polymers such as HPMC K4M, and Carbopol 934 were 
evaluated for drug-excipient compatibility, density, buoyancy test, swelling study, drug content and In-Vitro release profile. Sodium bicarbonate 
and citric acid were used producing effervescent base for buoyancy of tablets. Analysis of drug release from tablet indicates drug release by 
zero order, first order rate kinetics. No significant change was observed in physical appearance, drug content, floatability or in-vitro dissolution 
pattern after storage at 450C/750C RH for three months. 
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INTRODUCTION 
Oral drug administration still remains the route of choice for 
the majority of clinical applications some drug have ideal 
characteristics for good absorption to occur desirable for 
optimizing the therapeutic benefit of the drug1. Oral delivery 
of drugs is by far the most preferable route of drug delivery 
due to the ease of administration, patient compliance and 
flexibility in formulation2. Attempts have been made to be 8-
10 hr. From mouth to colon, is relatively brief with 
considerable fluctuation. One of the important determinants 
of G.I transit is the residence time in the stomach. The oral 
controlled delivery of drugs having “absorption window” 
continually releasing the drug prior to absorption window 
for prolonged period of time, thus ensuring optimal 
bioavailability3. A floating dosage unit is useful for drugs 
acting locally in the proximal gastrointestinal tract. These 
systems are also useful for drugs that are poorly soluble or 
unstable in intestinal fluids. Floating tablets and Floating 
capsules are common examples of floating system4,5. 
Effervescent Floating Drug Delivery System: 
A gastro retentive dosage form will release the drug over an 
extended period in the stomach and upper gastrointestinal 
tract (GIT) thus enhancing the opportunity for absorption. 
Various approaches have been proposed to control the 
gastric residence of drug delivery system in the upper part 
of the GIT including floating drug delivery system. High 
density DDS, bioadhesive systems, swelling and expanding 
DDS, modified shape systems and other delayed gastric 
devices5,6. FDDS is suitable for drugs with an absorption 
window in the stomach or the upper small intestine, for 
drugs which act locally in the stomach and for drugs that are 
poorly soluble or unstable in the intestinal fluid DDS or 
hydro dynamically balanced systems have a bulk density 
lower than gastric fluid and thus remain buoyant in the 
stomach without affecting the gastric emptying rate for a 
prolonged period of time. Based on the mechanism of 
buoyancy, two distinctly different technologies, i.e. non-
effervescent and effervescent systems, have been used in the 
development of FDDS6,7,8.  
The effervescent system uses matrices prepared with 
swellable polymers and effervescent components e.g. 
sodium bicarbonate and citric acid or stearic acid. In non-
effervescent FDDS, the drug mixes with a gel forming 
hydrocolloid, which swells in contact with gastric fluid after 
oral administration to maintain a relatively stable shape and 
a bulk density of less than unity within the outer gelatinous 
barrier9. 
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MATERIAL AND METHOD 
MATERIAL  
Preformulation Study of Drug: 
Preformulation testing is the first step in the rational 
development of dosage forms of a drug. It can be defined as 
an investigation of physical and chemical properties of drug 
substance, alone and when combined with excipients. The 
overall objective of preformulation testing is to generate 
information useful to the formulator in developing stable 
and bioavailable dosage forms, which can be mass-
produced10,11. 
Identification Tests 
a) Organoleptic Properties: 
The sample of Fluoxetine was studied for organoleptic 
characteristics such as colour, odour and appearance10,11. 
b) Melting Point: 
Melting point of Fluoxetine was determined by taking a 
small amount of sample in a capillary tube closed at one end 
and placed in melting point apparatus. The melting point 
was noted in triplicate and average value was noted10,11. 
c) IR Spectroscopy 
The FT-IR spectrum of the obtained sample of drug was 
compared with the standard FT-IR spectra of the pure drug. 
d) Solubility analysis: 
Preformulation solubility analysis was done to select a 
suitable solvent system to dissolve the drug and also to test 
its solubility in the dissolution medium which was to be 
used. 
e) Differential Scanning Calorimetry: 
The powdered sample (3 mg) was hermetically sealed in 
aluminium pans and heated at a constant rate 100C/min, 
over a temperature range of 30-3000C with nitrogen flow 
rate of 30ml/min. Thermograms of the samples were 
obtained using differential scanning Calorimetry (DSC-60, 
Shimadzu, Japan). Thermal analysis data were recorded with 
Shimadzu software programs. Indian standard was to 
calibrate the DSC temperature and enthalpy scale. 
Compatibility studies 
 a) IR Spectroscopy 
 Compatibility study was carried out by using Fourier 
Transform Infrared Spectrophotometer (BRUCKER). IR 
study was carried on pure drug. Physical mixture of drug 
and excipients were prepared and samples kept for 1 month 
at 400C. The infrared absorption spectrum of Fluoxetine and 
physical mixture of drug and excipient was recorded using 
diamond disc12,13.  
b) Preparation of 0.1 N HCL 
8.5 ml of concentrated HCL was taken and diluted with 
distilled water up to 1000 ml. 
c) Preparation of Standard Calibration curve of 
Fluoxetine 
The UV spectrum of Fluoxetine was obtained by using UV 
(Shimadzu UV - 1800, Japan). Accurately weighed 10 mg of 
the drug was dissolved in sufficient quantity of 0.1 N HCl and 
volume made up to 10 ml. The stock solution was diluted to 
obtain a concentration of 100 µg/ml. 1 ml of aliquot was 
withdrawn and  volume was made up to 10 ml using 0.1 N 
HCl to obtain the concentration of 10 µg/ml. The resultant 
solution was scanned from 400 to 200 nm and the spectrum 
was recorded to obtain the value of maximum Wavelength in 
respective solvents10,11. 
Formulation and Preparation of Effervescent Floating of 
Fluoxetine tablet by direct compression  
Weight all the ingredient accurately fist add polymer HPMC 
K4M in mortar then Carbopol 934 & Sodium bicarbonate mix 
it well for 10 min then add drug , magnesium stearate & 
lactose blend for 10 min at the last magnesium stearate 1% 
add mix all ingredient homogenously to form a tablet mix for 
direct compression14. 
Evaluation of powder 
The flow properties of granules (before compression) were 
characterized in terms of angle of repose, tapped density, 
bulk density, Carr’s index and Hausner’s ratio3,4,15.
 
Table No 2: Formulation Chart of Effervescent Floating Tablet of Fluoxetine 
Ingredients Formulation code 
Quantity (mg) F1 F2 F3 F4 F5 F6 F7 F8 F9 
Fluoxetine 75 75 75 75 75 75 75 75 75 
HPMC K4M 50 50 50 60 60 60 70 70 70 
Carbopol 934 10 15 20 10 15 20 10 15 20 
Sodium 
Bicarbonate 
30 30 30 30 30 30 30 30 30 
Citric acid 10 10 10 10 10 10 10 10 10 
Mg Stearate 3 3 3 3 3 3 3 3 3 
Lactose 47 42 37 37 32 27 27 22 17 
Total Weight 225 225 225 225 225 225 225 225 225 
 
Determination of Swelling Index:  
The swelling properties of matrices containing drug were 
determined by placing tablet matrices in the dissolution test 
apparatus in 900 ml 0.1 N HCl at 37 ± 0.50C. The tablets were 
removed periodically from the dissolution medium and, 
after removing free water, the weight gain was measured. 
The swelling characteristics were expressed in terms of the 
percentage water uptake (WU %) according to the equation5.  
Determination of Floating capacity:  
Three individual tablets from each formulation were put in 
an individual flask containing 400ml of 0.1 N HCl solutions. 
Then note time in minutes for each tablets to go from the 
bottom to the top of the flask (floating lag time) and the time 
for which tablets constantly float on the water surface 
(duration of floating) were measured. The sample mean and 
standard deviation were calculated. 
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In-vitro Disintegration Time: 
Disintegration time was determined using USP 
disintegration apparatus with distilled water. The volume of 
medium was 900 ml and temperature was 37 ± 0.20C. The 
time in minutes taken for complete disintegration of the 
tablet with no palatable mass remaining in the apparatus 
was measured. To comply the test all tablets should 
disintegrate within 15 minutes. 
Drug Content: 
Units were selected at random and drug content was 
determined as specified in monograph. The tablet 
preparation complies with the test, only if each individual 
content lies between 85 to 115% of the average content4.   
In Vitro drug release kinetics studies 
Kinetic model had described drug dissolution from solid 
dosage form where the dissolved amount of drug is a 
function of test time. In order to study the exact mechanism 
of drug release from the tablets, drug release data was 
analyzed according to zero orders, first order, Higuchi 
square root, korsmeyer peppas model. 
 
 
RESULT AND DISCUSSION  
Compatibility study by IR spectroscopy 
 
Figure 2: FTIR Spectrum of Fluoxetine 
 
The FTIR spectra of pure Fluoxetine showed the peaks at 
wave numbers (cm-1) which correspond to the functional 
groups present in the structure of the drug.  
Differential Scanning Calorimetry:- 
The powdered sample (3mg) was hermetically sealed in 
aluminium pans and heated at a constant rate 100C/min, 
over a temperature range of 30-3000C with nitrogen flow 
rate of 30ml/min. Thermograms of the samples were 
obtained using differential scanning Calorimetry (DSC-60, 
Shimadzu, Japan). Thermal analysis data were recorded with 
Shimadzu software programs. Indian standard was to 
calibrate the DSC temperature and enthalpy scale 
 
 
Fig.DSC Thermogram of Fluoxetine 
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Evaluation of Formulation: 
The Fluoxetine tablets were prepared by direct compression 
method. Ingredients were accurately weighed and passed 
through mesh. The powder blend was studied for rheological 
characteristics. The uniformly blend of powder was then 
compressed in a 10 station tablet punching machine using 
12 mm flat faced punches16. 
Before compression powder bed of all formulations were 
studied for various rheological characteristics bulk density, 
true density, compressibility index, Hausner’s ratio. The 
results of the studies indicated that the powder bed is easily 
compressible, and hence can be compressed into a compact 
mass of tablets. The angle of repose is an indicative 
parameter of powder Flowability from hopper to die 
cavity17. 
A repose angle between 250 to 300 indicates excellent 
Flowability of powder bed. In this work, the angle of repose 
was found to be varying between 22.810 and 26.720 when 
glidants were incorporated. These studies indicated that, the 
powder beds of all formulations are easily flowable. 
Evaluation of Pre-compressed parameters: 
All formulations were studied for various rheological 
characteristics bulk density, true density, compressibility 
index, Hausner’s ratio and angle of repose. The results of the 
studies indicated that the powder is blend is easily 
compressible.
 
Table 3: Pre-Compressed Evaluations 
Formulation 
code 
Bulk density 
(gm/ml) 
Tapped density 
(gm/ml) 
Angle of 
Repose (θ) 
Compressibility 
index (%) 
Hausner’s 
ratio 
F1 0.354±0.0030 0.411±0.0030 21.27±0.54 18.27±0.16 1.22±0.013 
F2 0.363±0.0021 0.427±0.0046 22.62±0.51 12.01±0.14 1.14±0.005 
F3 0.354±0.0033 0.418±0.0092 24.63±0.46 6.23±0.39 1.11±0.008 
F4 0.347±0.0039 0.453±0.0024 24.57±0.53 9.02±0.52 1.13±0.006 
F5 0.373±0.0041 0.442±0.0026 27.82±0.51 13.75±0.68 1.23±0.009 
F6 0.377±0.0019 0.410±0.0025 27.64±0.44 12.03±0.29 1.13±0.003 
F7 0.385±0.0036 0.458±0.0062 26.29±0.43 15.13±0.49 1.19±0.007 
F8 0.356±0.0035 0.442±0.0054 29.35±0.52 16.80±0.77 1.17±0.024 
F9 0.389±0.0024 0.467±0.0040 29.53±0.55 13.91±0.13 1.16±0.016 
 
Evaluation of Post Compressed Characteristics:  
The results of Hardness, Disintegration time, Drug content, Friability, Swelling index, Floating time all are summarized in the 
table given below: 
Table 4: Post-Compressed Evaluations 
Formulati
on code 
Hardness 
(kg/cm2) ± 
S.D. 
Drug content 
(%) ± S.D. 
(%) Friability 
± S.D. 
Swelling 
index % 
Thickness 
(mm) 
Weight 
Variation 
(mg) 
F1 3.32±0.057 97.35±0.040 0.174±0.037 34.07±0.69 3.69 ±0.63 224.13± 1.5 
F2 3.47±0.034 95.00±0.029 0.263±0.035 45.51±0.77 3.83±0.13 223.61±0.03 
F3 3.56±0.072 98.42±0.020 0.276±0.081 58.55±0.90 3.94±0.21 224.09±0.03 
F4 3.39±0.059 99.79±0.045 0.341±0.143 45.22±0.75 3.96±0.40 224.5±0.028 
F5 3.50±0.050 98.61±0.017 0.358±0.049 47.70±0.65 3.96±0.64 225.17±1.69 
F6 3.48±0.079 97.53±0.016 0.362±0.028 41.88±0.44 3.94±0.19 225.12±0.16 
F7 3.43±0.088 99.22±0.028 0.531±0.054 46.07±0.67 3.93±0.67 224.8±0.018 
F8 3.47±0.05 96.65±0.031 0.554±0.37 47.25±2.10 3.91±0.29 224 ± 0.018 
F9 3.79±0.03 98.14±0.029 0.615±0.42 49.40±0.56 3.93±0.10 225.35±0.25 
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In-Vitro Floating duration  
Table 5: Floating duration time and Floating lag time 
Formulation code F1 F2 F3 F4 F5 F6 F7 F8 F9 
Floating time (hr.) 12 12 12 12 12 12 12 12 12 
Floating lag time (sec) 55 68 80 104 122 151 166 212 224 
 
8.3.6. In Vitro drug release studies: 
 The dissolution studies were carried out for all nine formulations (i.e. F1 to F9) 
Table 6: Percent Cumulative drug release of different Formulations (F1-F9) 
Time 
(hr.) 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
1 6.36 
±1.98 
6.64 
±5.95 
7.57 
±2.15 
9.12 
±2.42 
7.78 
±2.06 
8.84 
±1.90 
8.06 
±2.02 
4.90 
±2.10 
5.70 
±1.53 
2 17.29 
±2.38 
21.68 
±1.93 
19.27 
±2.25 
15.79 
±1.74 
16.43 
±2.83 
16.67 
±2.32 
15.58 
±4.11 
10.15 
±2.04 
10.57 
±2.08 
3 25.42 
±2.06 
27.57 
±1.83 
25.14 
±2.05 
25.34 
±2.31 
19.06 
±1.99 
23.18 
±2.501 
17.46 
±2.05 
19.25 
±2.07 
12.86 
±2.84 
4 35.88 
±2.52 
31.58 
±2.54 
32.99 
±2.21 
31.70 
±1.58 
21.81 
±2.61 
29.81 
±2.49 
18.03 
±2.56 
24.45 
±2.83 
23.46 
±2.01 
5 39.84 
±1.87 
39.84 
±2.22 
40.14 
±1.94 
42.31 
±2.41 
25.34 
±1.91 
36.72 
±1.92 
22.24 
±1.93 
30.41 
±1.95 
30.41 
±1.90 
6 46.40 
±2.02 
48.55 
±2.39 
48.55 
±2.11 
47.24 
±2.15 
28.29 
±2.15 
38.05 
±1.9 
33.08 
±2.07 
37.90 
±1.90 
39.25 
±1.89 
7 55.16 
±2.10 
57.31 
±2.62 
57.39 
±1.99 
53.01 
±1.94 
31.84 
±1.95 
45.69 
±2.34 
36.87 
±2.00 
45.43 
±1.43 
47.58 
±4.95 
8 61.10 
±2.04 
65.66 
±2.19 
68.37 
±2.04 
62.00 
±2.17 
43.97 
±2.06 
49.72 
±2.06 
45.22 
±2.15 
53.01 
±2.11 
50.86 
±2.47 
9 64.98 
±2.07 
73.26 
±2.04 
75.24 
±2.54 
69.41 
±2.00 
54.99 
±2.00 
65.32 
±1.98 
53.29 
±2.01 
62.43 
±1.92 
55.16 
±1.81 
10 71.44 
±2.64 
80.21 
±2.03 
82.71 
±2.36 
76.94 
±1.86 
64.87 
±1.63 
76.74 
±2.45 
65.36 
±2.56 
70.44 
±1.36 
59.30 
±1.56 
11 76.73 
±2.42 
79.53 
±2.69 
86.63 
±1.96 
79.53 
±2.62 
82.36 
±1.25 
83.18 
±2.48 
70.61 
±2.00 
75.90 
±2.33 
65.37 
±2.06 
12 79.53 
±2.48 
84.48 
±2.09 
96.35 
±2.08 
81.72 
±2.08 
89.63 
±1.98 
88.82 
±2.63 
87.43 
±2.53 
77.87 
±1.88 
69.97 
±1.32 
 
Appearance  
The developed formulation met all the pre-requisite to become a floating effervescent  tablet, swelled and floated 
instantaneously at the acidic condition of the stomach. 
 
Figure 3: Effervescent  Floating tablet Formulation 
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In-Vitro release study 
 
Figure 4: Dissolution Profile of Formulation Batches (F1-F9) (Time Vs %CDR) 
A) Surface Response Plots: 
 
Figure 5: Surface Response plot showing effect of Carbopol 934 and HPMC K4M on drug release 
B) Contour plot: 
 
Figure 8: Contour plot showing effect of Carbopol 934 and HPMC K4M on drug release. 
 
Drug release kinetics 
In the present study, the drug release was analysed to study 
the kinetic of drug release mechanism. The results showed 
that the factorial design batches followed zero order and 
first order model kinetics, Higuchi and Connor’s model 
kinetics and kosemeyer’s peppas model kinetics20,21,22. 
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Zero-order comparative evaluation model kinetics: 
 
Figure 14: Model graph for comparative evaluation of zero order release kinetics 
First-order comparative evaluation model kinetics: 
 
Figure 15:  Model graph for comparative evaluation of First order release kinetics 
Higuchi and Connor’s model release kinetics: 
 
Figure 16: Model graph for comparative evaluation of Higuchi Connor’s release kinetics 
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Korsemeyer's peppas comparative evaluation model kinetics: 
 
Figure 17: Model graph for comparative evaluation of Korsemeyer's peppas release kinetics 
Stability Studies:  
Table 8: Stability study for optimized formulation F3 at 40±2ºC+75% RH   
Formulaton code 1 month 2 month 3 month 
F3 98.41 % ± 0.018 97.94 % ± 0.060 97.53 % ± 0.032 
 
The selected formulation were wrapped in aluminium foil 
and stored at 40 ± 2ºC and % RH 75% ± 5% temperature for 
3 months. After 3 months the formulation F3were evaluated 
for the hardness, drug content and in-vitro % drug release. It 
was observed that there was no significant variation in the 
physical appearance, average weight, hardness and loss of 
drying after placing the tablets at various temperature and 
humidity conditions for a period of 3 months. Also the 
cumulative % drug release data showed that each of the 
formulation released a drug amount, within the limits laid 
down as per the ICH guidelines for stability studies23. 
CONCLUSION: 
The present study was carried out to develop the 
effervescent floating drug delivery of fluoxetine using HPMC 
K4M and Carbopol 934 polymers as the carrier. Fluoxetine is 
BCS class I drug having high solubility and high permeability. 
Its oral bioavailability 55% and biological half-life is also 
approximately 14hrs. All the above reason are suitable for 
gastro retentive drug delivery system. After procurement of 
drug sample it was characterized for identification by FTIR. 
After identification check compatibility of drug with all 
excipient. It was found that it is compatible with all excipient 
there is no change in functional group. Physical property of 
Fluoxetine tablet i.e. hardness, friability, average weight, 
thickness also complies with standard reference. Floating lag 
time of all nine formulation show within one minute total 
floating time was more than 12 hrs.   
which are suitable for sustained release drug delivery 
system. The batch F3 shows 96.35% release in 12 hrs, so we 
concluded that rate of drug release increases in acidic 
environment of stomach. Release kinetic data of all the 
formulation show that F1-F9 formulation follows 
Korsmeyer-Peppas model. Stability study was conducted on 
tablets of batch F3 at 40±20C for 3 months.. From the 
discussion it was concluded that the Tablets of batch F3 was 
selected as optimum batch and evaluated for stability study. 
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